<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="80774"><DrugName>PTG-100</DrugName><DrugSynonyms><Name><Value>disulfide rich peptides, Protagonist</Value></Name><Name><Value>DRPs, Protagonist</Value></Name><Name><Value>alpha-4 beta-7 integrin antagonist (oral peptide/ DRP technology, inflammatory bowel diseases) Protagonist</Value></Name><Name><Value>PTG-100</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="30117">Protagonist Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="30117">Protagonist Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="30117" type="Company"><TargetEntity id="5037933405" type="organizationId">Protagonist Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"/><TargetEntity id="D015212" type="MeSH"/><TargetEntity id="-156308446" type="omicsDisease"/><TargetEntity id="394" type="siCondition"/></SourceEntity><SourceEntity id="2468" type="ciIndication"><TargetEntity id="K91.850" type="ICD10"/><TargetEntity id="10036463" type="MEDDRA"/><TargetEntity id="D019449" type="MeSH"/><TargetEntity id="-559402701" type="omicsDisease"/><TargetEntity id="2398" type="siCondition"/></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"/><TargetEntity id="10009900" type="MEDDRA"/><TargetEntity id="D003093" type="MeSH"/><TargetEntity id="-1993209976" type="omicsDisease"/><TargetEntity id="396" type="siCondition"/></SourceEntity><SourceEntity id="84" type="ciIndication"><TargetEntity id="K50" type="ICD10"/><TargetEntity id="10011401" type="MEDDRA"/><TargetEntity id="D003424" type="MeSH"/><TargetEntity id="-248155260" type="omicsDisease"/><TargetEntity id="395" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2950" type="Action"><TargetEntity id="1032" type="Mechanism">Integrin alpha4beta7 (LPAM-1) Antagonists</TargetEntity><TargetEntity id="3669" type="Mechanism">Anti-alpha4beta7</TargetEntity></SourceEntity><SourceEntity id="2617" type="Action"><TargetEntity id="3663" type="Mechanism">Integrin alpha4beta7 (MAdCAM) Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01067" type="ciTarget"><TargetEntity id="57611" type="siTarget">Integrin alpha4beta7 (LPAM-1) receptor</TargetEntity></SourceEntity><SourceEntity id="PTGT-01267" type="ciTarget"><TargetEntity id="81740" type="siTarget">Mucosal addressin cell adhesion molecule 1</TargetEntity><TargetEntity id="2724" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="189">Inflammatory bowel disease</Indication><Indication id="2468">Pouchitis</Indication><Indication id="337">Ulcerative colitis</Indication><Indication id="84">Crohns disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="2950">Integrin alpha-4/beta-7 antagonist</Action><Action id="2617">MAdCAM inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1332">Gastrointestinal system agent</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2018-12-02T15:02:59.000Z</LastModificationDate><ChangeDateLast>2019-01-08T00:00:00.000Z</ChangeDateLast><AddedDate>2012-09-10T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30117" linkType="Company"&gt;Protagonist Therapeutics&lt;/ulink&gt; was developing PTG-100, the lead from a series of disulfide rich peptides (DRPs), targeting  alpha-4 beta-7 integrin, developed using DRP technology platform, for the potential oral treatment of inflammatory bowel diseases (IBD) [&lt;ulink linkID="1321106" linkType="Reference"&gt;1321106&lt;/ulink&gt;], [&lt;ulink linkID="1568398" linkType="Reference"&gt;1568398&lt;/ulink&gt;], [&lt;ulink linkID="1618340" linkType="Reference"&gt;1618340&lt;/ulink&gt;], [&lt;ulink linkID="1676333" linkType="Reference"&gt;1676333&lt;/ulink&gt;].   However, in November 2018, the company replaced PTG-100 with &lt;ulink linkID="113589" linkType="Drug"&gt;PN-10943&lt;/ulink&gt; for the treatment of IBD, based on the superior  preclinical data on PN-10943 and recent feedback from the US FDA requesting an additional phase II dose ranging study with PTG-100 and considered to be the most efficient allocation of resources [&lt;ulink linkID="2099134" linkType="Reference"&gt;2099134&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2017, a phase IIb trial (PROPEL) was  initiated in patients with ulcerative colitis [&lt;ulink linkID="1892905" linkType="Reference"&gt;1892905&lt;/ulink&gt;]; in March 2018, the trial was discontinued for futility based on an analysis of the primary endpoint  [&lt;ulink linkID="2016928" linkType="Reference"&gt;2016928&lt;/ulink&gt;].  Also in March 2018, a phase II/III trial in patients with chronic pouchitis was planned [&lt;ulink linkID="2011414" linkType="Reference"&gt;2011414&lt;/ulink&gt;]; later  that month,   the company decided to postpone its decision about the initiation of the trial until after a full review of the interim data from the  PROPEL study  [&lt;ulink linkID="2016928" linkType="Reference"&gt;2016928&lt;/ulink&gt;]; in May 2018, an extensive review of the complete PROPEL dataset was underway. Following the review completion in 3Q18, the company would determine the further development of PTG-100 [&lt;ulink linkID="2032141" linkType="Reference"&gt;2032141&lt;/ulink&gt;]. In March 2017, Protagonist stated it planned to develop PTG-100 initially for the treatment of moderate-to-severe ulcerative colitis, followed by mild-to-moderate ulcerative colitis, Crohn's disease and pediatric IBD [&lt;ulink linkID="1969860" linkType="Reference"&gt;1969860&lt;/ulink&gt;]; in March 2018, the company planned to begin pivotal clinical development programs in Crohn's disease in 2019 [&lt;ulink linkID="2019693" linkType="Reference"&gt;2019693&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In March 2017, Protagonist stated it held one issued US patent and had one pending patent appliction directed to compositions of alpha-4 beta-7integrin peptides, as well as methods of synthesizing and using the peptides to treat inflammatory disorders. At that time, applications were pending in the US, Australia, Canada, China, Japan, and Europe. Patent applications directed to composition of matter and use of PTG-100 were expected to expire in October 2035, excluding patent term extensions.  Other patent applications if issued, were expected to expire from October 2033 to March 2037 [&lt;ulink linkID="1969860" linkType="Reference"&gt;1969860&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2018, following a positive decision from the interim futility analysis in the ulcerative colitis PROPEL study, the company planned to initiate a phase II/III trial in patients with chronic pouchitis in 2018 [&lt;ulink linkID="2011414" linkType="Reference"&gt;2011414&lt;/ulink&gt;]. Later that month, the company decided to postpone its decision about the initiation of the trial until after its full review of the interim data from the  PROPEL study [&lt;ulink linkID="2016928" linkType="Reference"&gt;2016928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2018, the company planned to begin pivotal clinical development programs in Crohn's disease in 2019 [&lt;ulink linkID="2019693" linkType="Reference"&gt;2019693&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2016, a randomized, double-blind, placebo-controlled, parallel, adaptive 2-stage, multi-center phase IIb study (&lt;ulink linkID="271257" linkType="Protocol"&gt;NCT02895100&lt;/ulink&gt;; PTG-100-02; PROPEL) to evaluate the safety and efficacy of oral PTG-100 induction in patients (expected n = 240) with moderate-to-severe active ulcerative colitis, was to begin in October 2016 in the US, Australia, Canada, Europe, South Korea and New Zealand . At that time, completion of the study was expected in May 2018 [&lt;ulink linkID="1796752" linkType="Reference"&gt;1796752&lt;/ulink&gt;]. In January 2017, the trial was initiated [&lt;ulink linkID="1892905" linkType="Reference"&gt;1892905&lt;/ulink&gt;]. In March 2018, the phase IIb trial was discontinued following a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients who had completed the 12 week treatment with PTG-100. Based on the pre-specified criteria, the DMC deemed the trial to be futile after an analysis of the primary endpoint of clinical remission. No safety concerns were observed. At that time, a full review of the interim data were underway [&lt;ulink linkID="2016928" linkType="Reference"&gt;2016928&lt;/ulink&gt;]. In May 2018, an extensive review of the complete dataset from all the enrolled patients in the trial was underway. Following the review completion in 3Q18, the company would determine the further development of PTG-100 [&lt;ulink linkID="2032141" linkType="Reference"&gt;2032141&lt;/ulink&gt;]. In August 2018, results from an independent blinded re-analysis data were reported. The data from blinded endoscopy re-reads and a comprehensive data review provided signals of clinical efficacy and support further development of PTG-100. A re-read of the endoscopies by the CRO's subcontractor and a subsequent fully blinded re-read of the endoscopies by an independent third party, Robarts Clinical Trials, confirmed that a subset of the initial endoscopy reads provided by the CRO were in error. If the re-read of endoscopy results had been utilized for the interim futility analysis, the trial would have continued.  In addition, improvements observed in independent, blinded histological scores favor PTG-100 over placebo and correlate with the clinical remission and endoscopic response outcomes from the re-analysis. At that time,the company expected to  meet with the FDA during the second half of 2018 to discuss next steps and planned to present the PROPEL data at a future medical conference [&lt;ulink linkID="2060124" linkType="Reference"&gt;2060124&lt;/ulink&gt;]. In October 2018, data from the trial were presented at the 2018 United European Gastroenterology Week, held in Vienna, Austria. PTG-100 was well tolerated and associated with high rates of clinical remission, compared to placebo. The dose-dependent increase in rates of histologic remission, the blood biomarker data and topline safety data expand upon the clinical remission and endoscopic response results announced  in August 2018 that involved an independent, blinded re-analysis of endoscopies and demonstrated signals of clinical efficacy [&lt;ulink linkID="2091191" linkType="Reference"&gt;2091191&lt;/ulink&gt;]. Further data were presented at the same conference. At PTG-100 dose of 900 mg, an increase in clinical remission, endoscopic response, and histologic remission (15.8, 15.8 and 44%, respectively) with maximal efficacy versus placebo (4.8, 4.8 and 0%, respectively) or PTG-100 150 (9.1, 9.1 and 15%, respectively) and 300 mg qd (9.5, 14.3 and 22%, respectively) was observed. Overall, PTG-100 was well tolerated with low rates of adverse events (AEs), serious AEs and discontinuations [&lt;ulink linkID="2090935" linkType="Reference"&gt;2090935&lt;/ulink&gt;], [&lt;ulink linkID="2085511" linkType="Reference"&gt;2085511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2015,  phase I/II trials were expected to begin by the end of 2015 and during 2016, respectively   [&lt;ulink linkID="1678147" linkType="Reference"&gt;1678147&lt;/ulink&gt;].  In August 2015, phase IIa proof-of-concept studies were expected in  [&lt;ulink linkID="1689567" linkType="Reference"&gt;1689567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In July 2015,  phase I trials were expected to begin by the end of 2015 and during 2016 [&lt;ulink linkID="1678147" linkType="Reference"&gt;1678147&lt;/ulink&gt;].  In August 2015, phase Ia/Ib pharmacodynamic based proof-of-concept studies were expected in  2016 [&lt;ulink linkID="1689567" linkType="Reference"&gt;1689567&lt;/ulink&gt;]. In April 2016, it was reported at CHI's eleventh Drug Discovery Chemistry conference in San Diego, CA that a phase I study in ulcerative colitis started in December 2015 [&lt;ulink linkID="1756721" linkType="Reference"&gt;1756721&lt;/ulink&gt;]. In August 2016, it was reported at the 252nd ACS meeting in Philadelphia, PA that  completed phase I trials for moderate-to-severe ulcerative colitis had been completed [&lt;ulink linkID="1789249" linkType="Reference"&gt;1789249&lt;/ulink&gt;], [&lt;ulink linkID="1790485" linkType="Reference"&gt;1790485&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2014,  the company planned to file an IND to initiate phase I trials for PTG-100 	[&lt;ulink linkID="1618340" linkType="Reference"&gt;1618340&lt;/ulink&gt;].	 In June 2015, the drug was in phase I or phase 0 development [&lt;ulink linkID="1676333" linkType="Reference"&gt;1676333&lt;/ulink&gt;]. In January 2016, a randomized, double-blind, placebo-controlled, dose-escalation phase I trial was initiated in normal healthy volunteers (expected n = 70) in Australia [&lt;ulink linkID="1725863" linkType="Reference"&gt;1725863&lt;/ulink&gt;].   In October 2016, results were presented at the 24th UEG Week in Vienna, Austria. Male normal healthy volunteers (n = 70) received once daily dosing of PTG-100 for 14 days in the multiple ascending dose  portion. Dose escalation of PTG-100 proceeded to 1000 mg (highest planned dose in the study) in the single ascending dose  portion (n = 40). Serious adverse events or DLTs were not reported. Although plasma concentrations of PTG-100 were extremely low, there were dose-dependent increases in plasma levels. Following a single dose exposure of PTG-100, blood receptor occupancy (RO) increased in a dose-dependent manner in memory T cells, naive T cells and B cells and these increases in RO sustained beyond 24 h [&lt;ulink linkID="1868578" linkType="Reference"&gt;1868578&lt;/ulink&gt;]. In August 2018, similar data were presented at the 256th ACS National Meeting and Exposition in Boston, MA [&lt;ulink linkID="2064762" linkType="Reference"&gt;2064762&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In August 2018, preclinical data were presented at the 256th ACS National Meeting and Exposition in Boston, MA. PTG-100 exhibited IC50 value of 1 nM against of alpha 4 beta 7 integrin. PTG-100 had t1/2 and oral bioavailability of 24 h and 0.5%, respectively. PTG-100 was found to be effective at 6 to 55 mg/kg in mouse [&lt;ulink linkID="2064762" linkType="Reference"&gt;2064762&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In October 2016, preclinical data were presented at the 24th UEG Week in Vienna, Austria.  In normal or dextran sodium sulfate (DSS)-treated mice and rats, PTG-100 (po) showed dose-dependent exposure in the small intestine, colon, and Peyer's patches while very low exposures were observed in the blood and urine. PTG-100 exhibited po bioavailability of &amp;lt; 0.5% in mice (indicate gut restricted) and in cynomolgus monkeys (and up to 40% in feces). PTG-100 qd po dosing resulted in a dose-dependent increase in RO of memory T-cells and increase in alpha-4-beta-7 memory CD4 (+) T-cells in the peripheral blood of cynomolgus monkeys [&lt;ulink linkID="1868574" linkType="Reference"&gt;1868574&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, preclinical data were presented at the 252nd ACS meeting in Philadelphia, PA. In a  proof-of-concept colitis model in mice PTG-100 showed a blockage of T-cells trafficking in GI tissues and a clear reduction of the disease pathology at an efficacy dosage of 6 to 50 mg/kg [&lt;ulink linkID="1789249" linkType="Reference"&gt;1789249&lt;/ulink&gt;], [&lt;ulink linkID="1790485" linkType="Reference"&gt;1790485&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, preclinical data were presented at the 2016 DDW in San Diego, CA. In BALB/c mice model with dextran sulfate sodium colitis, treatment with PTG-100 total daily dose (combination of po gavage bid, plus drug in drinking water) reduced disease activity index AUC score and number of beta 7+ cells, when compared with DATK-32. In cynomolgus monkeys, blood receptor occupancy of CD4+ alpha-4-beta-7+ memory T cells was similar with PTG-100 (12.5 mg/kg, po, qd) under fasted and non-fasted conditions [&lt;ulink linkID="1762934" linkType="Reference"&gt;1762934&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at CHI's eleventh Drug Discovery Chemistry conference in San Diego, CA. In preclinical studies, PTG-100 was stable in GI fluids, maintained microbiome stability, and did not have antimicrobial activities. In addition, PTG-100 had a long resident time and demonstrated similar potency to vedolizumab. Exposure was largely restricted to GI tissues [&lt;ulink linkID="1756721" linkType="Reference"&gt;1756721&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2014, preclinical data had demonstrated that the program showed a positive outcome in a 42-day chronic gold standard intervention model of IBD and at that time, the company was planning to select the first development candidate in 2014 [&lt;ulink linkID="1568398" linkType="Reference"&gt;1568398&lt;/ulink&gt;]. In December 2014, IND-enabling studies were ongoing [&lt;ulink linkID="1618340" linkType="Reference"&gt;1618340&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate>2018-03-26T00:00:00.000Z</StatusDate><Source id="2016928" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate>2018-03-26T00:00:00.000Z</StatusDate><Source id="2016928" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate>2018-03-26T00:00:00.000Z</StatusDate><Source id="2016928" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate>2018-03-26T00:00:00.000Z</StatusDate><Source id="2016928" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="2468">Pouchitis</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099134" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099134" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate>2018-03-26T00:00:00.000Z</StatusDate><Source id="2016928" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="84">Crohns disease</Indication><StatusDate>2018-11-27T00:00:00.000Z</StatusDate><Source id="2099134" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate>2018-03-26T00:00:00.000Z</StatusDate><Source id="2016928" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2011-10-07T00:00:00.000Z</StatusDate><Source id="1321106" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2015-06-18T00:00:00.000Z</StatusDate><Source id="1676333" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2015-12-31T00:00:00.000Z</StatusDate><Source id="1756721" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2017-01-17T00:00:00.000Z</StatusDate><Source id="1892905" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2017-01-17T00:00:00.000Z</StatusDate><Source id="1892905" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2017-01-17T00:00:00.000Z</StatusDate><Source id="1892905" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2017-01-17T00:00:00.000Z</StatusDate><Source id="1892905" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2017-01-17T00:00:00.000Z</StatusDate><Source id="1892905" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2017-01-17T00:00:00.000Z</StatusDate><Source id="1892905" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate>2017-03-07T00:00:00.000Z</StatusDate><Source id="1969860" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2016-01-08T00:00:00.000Z</StatusDate><Source id="1725863" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30117">Protagonist Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2468">Pouchitis</Indication><StatusDate>2018-03-07T00:00:00.000Z</StatusDate><Source id="2011414" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01067"><Name>Integrin alpha-4/beta-7</Name><SwissprotNumbers><Swissprot>P13612</Swissprot><Swissprot>P26010</Swissprot><Swissprot>P26011</Swissprot><Swissprot>Q00651</Swissprot><Swissprot>Q91687</Swissprot><Swissprot>Q9V7A4</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01267"><Name>MAdCAM</Name><SwissprotNumbers><Swissprot>O70540</Swissprot><Swissprot>Q13477</Swissprot><Swissprot>Q61826</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2717599" number="WO-2014059213" title="Novel α4β7 peptide dimer antagonists"/><PatentFamily id="3067499" number="WO-2015176035" title="Α4β7 integrin thioether peptide antagonists"/><PatentFamily id="3160930" number="WO-2016054445" title="Novel cyclic monomer and dimer peptides having integrin antagonist activity"/><PatentFamily id="3601845" number="WO-2016054411" title="Novel α4β7 peptide monomer and dimer antagonists"/><PatentFamily id="3799932" number="WO-2017165676" title="Methods for synthesizing α4β7 peptide antagonists"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protagonist Therapeutics Inc" id="30117"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>